biotech · Choroideremia · X-Linked Retinitis Pigmentosa · FDMT
4D Molecular Therapeutics
4D Molecular Therapeutics clinical programs — 9 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 5858 Horton St, 455, Emeryville, California 94608, US
- Founded
- 2013
- Employees
- 213
- Programs
- 19
- Drugs
- 13
- Patents
- 15
4D Molecular Therapeutics projects
9 ClinicalTrials.gov programs sponsored by 4D Molecular Therapeutics.
4D Molecular Therapeutics has 9 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
4D-125 IVT Injection
4D Molecular Therapeutics
X-Linked Retinitis Pigmentosa
1 trial -
4D-150 IVT
4D Molecular Therapeutics
Diabetic Macular Edema
1 trial -
4D-150 IVT
4D Molecular Therapeutics
Neovascular (Wet) Age-Related Macular Degeneration
1 trial -
4D-310
4D Molecular Therapeutics
Fabry Disease
2 trials -
4D-710
4D Molecular Therapeutics
Cystic Fibrosis Lung
1 trial -
Blautix
4D Molecular Therapeutics
Irritable Bowel Syndrome
1 trial -
MRx-4DP0004
4D Molecular Therapeutics
COVID-19
1 trial -
MRx0518
4D Molecular Therapeutics
Oncology
1 trial -
MRx0518
4D Molecular Therapeutics
Urothelial Carcinoma
1 trial
Frequently asked questions
How many clinical projects does 4D Molecular Therapeutics have?
9 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.